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Penn Veterinary Medicine Alumni Discover Rewarding Careers in Biotech
By Nancy West

During the past decade, growth in the
biotechnology industry has exploded with U.S.
revenues increasing nearly ﬁvefold, from $8
billion in 1992 to $39.2 billion in 2003. During
roughly the same period, research and development spending in the U.S. biotech industry more
than doubled from $7 billion to $17.9 billion,
while the number of biotechnology patents
granted per year more than tripled from about
2,500 in 1992 to nearly 7,800 in 2002. Employment in the industry soared from 103,000 in
1994 to more than 198,000 in 2003.
Attracted by a wide range of opportunities, a
growing number of Penn Veterinary Medicine
alumni are ﬁnding rewarding careers in
biotechnology where they enjoy the advantages
of a resource-rich industry and entrepreneurial
spirit as well as the excitement of research and
discovery that has the potential to enhance
human and animal health.
Following are the stories of three Penn alumni
who have found success and fulﬁllment in the
biotechnology ﬁeld.

Douglas J. Ringler, C’79, V’83:
A Promising Therapy for Type I Diabetes
During his teenage years in upstate New York,
Doug Ringler, C’79, V’83, worked at a mixed
veterinary practice where a large number of the
patients were dairy cows. He loved the experience and had every intention of joining the
practice after ﬁnishing veterinary school. Instead,
he joined a small-animal practice in Boston and,
after just a few months, made a discovery that
was surprising even to him. Although he enjoyed
veterinary practice, he wanted something more.
“I quickly found myself looking for the next
challenge in my career,” Dr. Ringler recalls.
“I wanted to work on new goals that would
complement what I had already experienced, so I
decided to return to academia.”
After completing a residency and a post-doctoral fellowship in pathology at Harvard Medical
School, Dr. Ringler joined the school’s medical
faculty. During his 10 years at Harvard, he ultimately served as associate professor of pathology
and chairman of the Division of Comparative
Pathology, and directed a pathology lab of 20
pursuing research in inﬂammatory mechanisms.
In 1993, Dr. Ringler decided it was time to
move on to the next phase of his career—translating basic research ﬁndings into the clinical

venue. That year, he ventured into the biotech
industry as a founding scientist and executive
ofﬁcer of LeukoSite, Inc., a biotech company
focused on the development of therapies to alter
immunological responses.
Five years later, the successful company was
sold to Millennium Pharmaceuticals, which
marketed two products based on the research
and development done by Dr. Ringler and his
colleagues, including Campath®, a monoclonal
antibody for refractory chronic lymphocytic

psoriasis, and expects to begin Phase I trials this
year with a second product designed to induce
tolerance in transplantation, autoimmune
diseases such as lupus, and clinical situations
where the immune system attacks therapeutic
proteins or biologic drugs, such as Factor VIII in
hemophilia A.
“Biotech is a terriﬁc career path for a
veterinarian,” says Dr. Ringler. “Very few careers
give you the opportunity to participate in drug
discovery and development at all levels of the
process. You can start at the bench and take it
all the way to the patient’s bedside, which is
tremendously rewarding. Veterinary training,
especially at Penn, gives you a unique perspective
that is very valuable in this process.”

Mark J. Pykett, V’91,PhD’94, MBA:
Developing CNS Diagnostics and Therapeutics

Douglas J. Ringler

leukemia, and Velcade®, a treatment for multiple
myeloma. Another biotech ﬁrm, Genzyme,
acquired the rights to and is now developing
Campath® as a treatment for multiple sclerosis.
Today, Dr. Ringler is president and CEO
of TolerRx, a biopharmaceutical company he
co-founded in 2000 to focus on the discovery,
development, and commercialization of novel
therapies to treat patients with immunological
diseases, including Type I diabetes, psoriasis, and
hemophilia A.
“We are now moving toward Phase III testing
in humans with a monoclonal antibody that we
believe can very signiﬁcantly change the disease
course in Type I diabetics,” says Dr. Ringler,
noting that an article will soon appear in the
New England Journal of Medicine about these
unprecedented ﬁndings.
“Knowing that your efforts are beneﬁting
others is tremendously rewarding,” he says. “We
expect this product to modulate the disease
course in children, young adults, and adults with
Type I diabetes. We hope to signiﬁcantly reduce
the side effects from the disease that are largely
vascular related.”
TolerRx is also running Phase I clinical
trials on the same product for the treatment of

The research lab was always the end goal
for Mark Pykett, V’91, PhD’94, MBA. Now
president and chief operating ofﬁcer of Boston
Life Sciences, Inc., a biotechnology company
focused on research and clinical development of
diagnostic and therapeutic products for central
nervous system (CNS) disorders, Dr. Pykett
says that he was motivated to attend veterinary
school for his training because he believed it
would give him the best, broad-based training.
He was not disappointed.
“I chose Penn because of the Veterinary Medical Scientist Training Program,” he says. “I liked
the fact that this combined VMD/PhD degree
program was well integrated between the vet
school and the graduate research environment.”
Dr. Pykett also believed that the diversity of
species, conditions and diseases encountered in
veterinary school would provide him with better
interdisciplinary approaches, better translational
capabilities, and a better ability to think outside
the box and extrapolate ﬁndings between species.
After completing the program and a
post-doctoral fellowship at Penn, he moved on
to Harvard School of Public Health, where he
completed a second post-doctoral fellowship on
the molecular basis of cancer and then held an
adjunct faculty position for ﬁve years.
Dr. Pykett expected to remain in an academic
career, but switched gears when he became interested in Boston’s hot biotechnology industry.
“While at Harvard, I had the opportunity to see
the entrepreneurial side of medical research,” he
(continued on page 30)
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recalls. “At about the same time, I learned about
a technology that I thought had interesting
prospects as the seed for a biotech company.”
Together with the inventor of the technology and a colleague from Penn, Dr. Pykett
co-founded and served as president and CEO
for Cytomatrix, a startup company that focused
on developing cell therapeutics. Later, he served
as president of Cordlife, a cell therapy biotech
company that acquired his successful company,

Mark J. Pykett

and of CyGenics, a global adult stem cell and cell
therapy biotech company.
Since 2004, he has overseen operations at
Boston Life Sciences, Inc. (BLSI). He also serves
on the board of directors of several public and
private biotech companies. The current lead
product in the BLSI pipeline is ALTROPANE®, a
diagnostic imaging agent for the early diagnosis
of Parkinson’s disease, which is currently in Second Phase III clinical trials. “Our goal is to show
that ALTROPANE® will improve the medical
community’s ability to differentiate Parkinson’s
disease from non-Parkinsonian movement
disorders,” says Dr. Pykett. ALTROPANE® is also
in Phase II clinical trials for use in objectively
diagnosing attention deﬁcit hyperactivity
disorder (ADHD). Other products in the
pipeline include a nerve growth factor for the
treatment of stroke and spinal cord injury and a
novel DAT (dopamine transporter) blocker for
the treatment of Parkinson’s disease.
“The challenge of bringing innovations
through the entire development and commercialization process that, hopefully, will lead
to a product that can enhance the lives of many
people is extremely rewarding,” states Dr. Pykett.
“The biotech industry offers a host of beneﬁts
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to veterinarians who are interested in research,”
he notes. “In smaller biotech companies, you
have the opportunity to be entrepreneurial and
innovative and play a leadership role very early
in your career. For me, the incentives, ﬂexibility,
and autonomy in the biotech industry, combined
with the opportunity to do innovative work that
moves at a rapid pace, have brought a tremendous amount of career satisfaction.”

Kenneth L. Mohn, V’88, PhD’91:
Research and Discovery in Large Pharma
As a boy growing up at the edge of
the Pine Barrens in Tom’s River, N.J.,
Ken Mohn, V’88, PhD’91, spent a lot of time
in the woods catching snakes, lizards, and other
creatures, observing them for a while, then
letting them go free. “I always loved animals
and related well to them,” recalls Dr. Mohn.
“Everyone said, ‘You should be a veterinarian.’
But I wanted to be a Marlin Perkins or Jacques
Costeau. That seemed more exciting.”
Nevertheless, Dr. Mohn decided to pursue a
veterinary career. “I grew up in a strong Christian
home and I believed that was God’s direction for
my life,” he says. While pursuing an undergraduate degree in animal science at Rutgers University,
he had the opportunity to work on a highly
successful honors research project. That experience ignited his interest in a career that would
combine his love of animals and research.
“In the midst of that project, I was applying to veterinary schools,” explains Dr. Mohn.
“When I saw the Veterinary Medical Scientist
Training Program in Penn’s brochure, I knew
that was the place for me.”
While in school, he completed a lab animal
medicine rotation at Merck. “I was intrigued by
the pharmaceutical industry and the opportunity to do practically oriented research in a
well-funded organization,” he states. In 1992, he
joined Merck’s Basic Animal Science Research
group, which focuses on the development of
novel veterinary pharma products.
Serving ﬁrst as a research fellow and then
research veterinarian during the past 13 years,
Dr. Mohn has worked on a wide range of projects, from allergy treatments for dogs and cats
to feline dental products to growth promotants
for pigs and cattle to poultry products, and even
some human-health products.
Currently, he is in charge of a parasitology
laboratory looking for a broad spectrum anti-

parasitic drug with the potential to take the place
of ivermectin.
Dr. Mohn holds a patent for a product
developed to treat feline dental resorptive
lesions, which he is hopeful will reach the
marketplace. He also takes pride in his contributions to a reproductive control project in which
his veterinary training played a key role. “My
observations evolved into an exciting program to
develop a reproductive control vaccine targeted
primarily to the pork industry,” he says.

Kenneth L. Mohn

Dr. Mohn enjoys the fact that, in addition to
research, he is also responsible for the health of
horses, cattle, swine, chickens, and sheep residing
at Merck’s 200-acre research farm where he has
worked for the past ﬁve years. “I really missed
the hands-on contact with animals when I was
just working in the lab,” he relates. “Now I have
the opportunity to treat a horse or a cow and
to run some in vivo studies while maintaining a
productive in vitro laboratory. . . it’s the best of
both worlds.”
Dr. Mohn has found his veterinary training invaluable throughout his career. “I’ve led
many multidisciplinary project teams because
of my diverse training,” he notes. “It helps
tremendously in understanding the process for
which we’re trying to develop a therapy and for
developing valid animal models.”
The rewards of research work at a large
pharma company are enormous, he says. “In
addition to signiﬁcant ﬁnancial beneﬁts, you
have huge opportunities to be creative and apply
your veterinary skills to pursue a goal that may
have a very signiﬁcant impact on animal health
worldwide and contribute to human health as
well. It’s exciting to think that your discoveries
may ultimately change the way people practice
medicine.” ■

